-- 
Intercell Rises on Completion Phase II/III Encephalitis Vaccine

-- B y   Z o e   S c h n e e w e i s s
-- 
2011-09-16T07:08:33Z

-- http://www.bloomberg.com/news/2011-09-16/intercell-rises-on-completion-phase-ii-iii-encephalitis-vaccine.html
Intercell AG (ICLL) , the Austrian
biotechnology company, rose the most in a month in intraday
trading after saying that it “successfully” completed its phase
II/III study of a Japanese Encephalitis vaccine for children.  Shares rose as much as 9.4 percent and was trading up 7.3
percent at 2.11 euros at 9:08 a.m. in Vienna.  To contact the editor responsible for this story:
Zoe Schneeweiss at 
 zschneeweiss@bloomberg.net  